Washington D.C., District of Columbia
Phase 1 cancer trials in Washington D.C., DC
36 Phase 1 cancer studies are recruiting participants at sites in Washington D.C. as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Washington D.C. at a glance
- 36 studies are recruiting at a site in Washington D.C..
- By phase: Phase 1 (13), Phase 1/2 (23).
- By sponsor: industry (26), university, hospital or other (8), government (2).
- By research area: Lung Cancer (16), Breast Cancer (8), Lymphoma (6), Melanoma (3), Prostate Cancer (2), Pancreatic Cancer (1).
- Most recent update to one of these records: November 17, 2026.
Breast cancer studies recruiting in Washington D.C.
Basic details from each study's public record (the 30 most recently updated of 36). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pliant Therapeutics, Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT06270706 · updated
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Phase 1
- Ages 18 to 55
- Female participants
- Sponsor
- TerSera Therapeutics LLC
- Study site
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center
- Registry record
- NCT07310420 · updated
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- ORIC Pharmaceuticals
- Study site
- Georgetown University
- Registry record
- NCT05315700 · updated
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- NiKang Therapeutics, Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT07029399 · updated
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- SystImmune Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT05983432 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Lung cancer studies recruiting in Washington D.C.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT05786924 · updated
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- MedStar Georgetown University Hospital
- Registry record
- NCT06287775 · updated
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- IDEAYA Biosciences
- Study site
- Johns Hopkins Sibley Memorial Hospital
- Registry record
- NCT07277413 · updated
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Georgetown University - Lombardi Comprehensive Cancer Center
- Registry record
- NCT07111520 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Georgetown University
- Registry record
- NCT04886804 · updated
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Phase 1/2
- Ages 18 to 80
- All sexes
- Sponsor
- VM Oncology, LLC
- Study site
- The George Washington University Cancer Center (site 212)
- Registry record
- NCT03556228 · updated
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BlossomHill Therapeutics
- Study site
- Georgetown University Medical Center
- Registry record
- NCT06706076 · updated
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Synthekine
- Study site
- Georgetown University
- Registry record
- NCT05098132 · updated
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tango Therapeutics, Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT06922591 · updated
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Tango Therapeutics, Inc.
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT06810544 · updated
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT06162221 · updated
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Phase 1/2
- Ages 18 to 75
- All sexes
- Sponsor
- Avenzo Therapeutics, Inc.
- Study site
- Avenzo Therapeutics Recruiting Site
- Registry record
- NCT07038343 · updated
A Study of PHN-012 in Patients With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pheon Therapeutics
- Study site
- PHN-012-001 Site
- Registry record
- NCT07127874 · updated
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Registry record
- NCT07407933 · updated
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Sutro Biopharma, Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT07227168 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Prostate cancer studies recruiting in Washington D.C.
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026)
- Registry record
- NCT06863272 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- Johns Hopkins University, Sibley Memorial Hospital
- Registry record
- NCT05919264 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Melanoma studies recruiting in Washington D.C.
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
- Phase 1
- Ages 3 to 25
- All sexes
- Sponsor
- Children's National Research Institute
- Study site
- Children's National Hospital
- Registry record
- NCT07796061 · updated
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Sibley Memorial Hospital
- Registry record
- NCT05896839 · updated
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Phase 1/2
- From 12 months, up to 30 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Children's National Medical Center
- Registry record
- NCT04851119 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Lymphoma studies recruiting in Washington D.C.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Phase 1/2
- Up to age 22
- All sexes
- Sponsor
- PedAL BCU, LLC
- Study site
- Children's National Medical Center
- Registry record
- NCT04726241 · updated
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- Nuvalent Inc.
- Study site
- Georgetown University Medical Center
- Registry record
- NCT05384626 · updated
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
- Phase 1
- Ages 4 and older
- All sexes
- Sponsor
- University of Florida
- Study site
- Children's National Hospital
- Registry record
- NCT04573140 · updated
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Phase 1/2
- From 12 months, up to 21 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Children's National Medical Center
- Registry record
- NCT04870944 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Washington D.C.
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Artios Pharma Ltd
- Study site
- The Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins)
- Registry record
- NCT04657068 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Washington D.C., DC on ClinicalTrials.gov.
Ask about studies near Washington D.C.
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.
Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections